Breaking News Instant updates and real-time market news.

MSFT

Microsoft

$203.86 /

+2.04 (+1.01%)

14:00
07/29/20
07/29
14:00
07/29/20
14:00

Microsoft unveils Microsoft Family Safety app

Liat Ben-Zur, Corporate Vice President, Modern Life, Search, and Devices for Microsoft wrote in a blog post earlier: "Today, we are excited to announce that the Microsoft Family Safety app, designed to help you protect your family's digital and physical safety, is starting to rollout today on iOS and Android. Over the past few months, I have been using the preview with my family, and it has been a game-changer! As a kid, my two favorite things to do after school were to ride my bike and play soccer with my neighborhood friends. Nowadays, my kids are always on their devices, whether playing video games with their friends, on social media or learning remotely. Kids have access to more information and endless ways to connect with other people. This can be scary for parents. As a mom, I seek to give my kids the independence to learn and grow whilst ensuring that they are also safe online and in the real world. Today, I am excited to share with you how any family worried about their kids' online safety can benefit from the Microsoft Family Safety app and how it has helped us to create healthier habits for my kids, while also giving my wife and me peace of mind." Here are the top 5 ways my family has benefited from the Microsoft Family Safety app: 1. Use the weekly activity report as a conversation starter.2. Limit screen time for play and make more time for learning. 3. Set healthy boundaries with web and search filters. 4. Get purchase request emails to avoid surprise spending. " Reference Link

MSFT Microsoft
$203.86 /

+2.04 (+1.01%)

07/27/20 Morgan Stanley
Morgan Stanley downgrades Software industry view to In-Line from Attractive
07/23/20
Fly Intel: Top five analyst downgrades
07/23/20 Wedbush
Microsoft remains top cloud name at Wedbush
07/23/20 Bernstein
Microsoft quarter not perfect 'but really good' given COVID, says Bernstein

TODAY'S FREE FLY STORIES

Hot Stocks
Arbutus Biopharma expects to complete IND-enabling studies of AB-836 by year-end » 07:44
08/07/20
08/07
07:44
08/07/20
07:44
ABUS

Arbutus Biopharma

$4.39 /

+0.215 (+5.16%)

In January 2020, Arbutus…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ABUS Arbutus Biopharma
$4.39 /

+0.215 (+5.16%)

ABUS Arbutus Biopharma
$4.39 /

+0.215 (+5.16%)

07/27/20 B. Riley FBR
Arbutus Biopharma price target raised to $8 from $6 at B. Riley FBR
07/24/20 Baird
Arbutus Biopharma upside priced in, Baird downgrades to Neutral
07/24/20 Baird
Arbutus Biopharma downgraded to Neutral from Outperform at Baird
05/19/20 Wedbush
Arbutus Biopharma upgraded to Outperform at Wedbush following AB-729 data
ABUS Arbutus Biopharma
$4.39 /

+0.215 (+5.16%)

ABUS Arbutus Biopharma
$4.39 /

+0.215 (+5.16%)

Recommendations
AMN Healthcare price target raised to $65 from $50 at BMO Capital » 07:43
08/07/20
08/07
07:43
08/07/20
07:43
AMN

AMN Healthcare

$55.22 /

-0.7 (-1.25%)

BMO Capital analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
AMN AMN Healthcare
$55.22 /

-0.7 (-1.25%)

AMN AMN Healthcare
$55.22 /

-0.7 (-1.25%)

07/21/20 SunTrust
AMN Healthcare upgraded to Buy from Hold at SunTrust
07/21/20 SunTrust
AMN Healthcare upgraded to Buy from Hold at SunTrust
05/13/20 BMO Capital
AMN Healthcare price target lowered to $50 from $79 at BMO Capital
05/12/20 Credit Suisse
AMN Healthcare price target lowered to $62 from $81 at Credit Suisse
AMN AMN Healthcare
$55.22 /

-0.7 (-1.25%)

AMN AMN Healthcare
$55.22 /

-0.7 (-1.25%)

Hot Stocks
Arbutus expects results from cohort in AB-729 trial in 2H20 » 07:43
08/07/20
08/07
07:43
08/07/20
07:43
ABUS

Arbutus Biopharma

$4.39 /

+0.215 (+5.16%)

Arbutus is dosing two 60…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ABUS Arbutus Biopharma
$4.39 /

+0.215 (+5.16%)

ABUS Arbutus Biopharma
$4.39 /

+0.215 (+5.16%)

07/27/20 B. Riley FBR
Arbutus Biopharma price target raised to $8 from $6 at B. Riley FBR
07/24/20 Baird
Arbutus Biopharma upside priced in, Baird downgrades to Neutral
07/24/20 Baird
Arbutus Biopharma downgraded to Neutral from Outperform at Baird
05/19/20 Wedbush
Arbutus Biopharma upgraded to Outperform at Wedbush following AB-729 data
ABUS Arbutus Biopharma
$4.39 /

+0.215 (+5.16%)

ABUS Arbutus Biopharma
$4.39 /

+0.215 (+5.16%)

Earnings
Sabre reports Q2 adjusted EPS ($1.30), consensus (84c) » 07:42
08/07/20
08/07
07:42
08/07/20
07:42
SABR

Sabre

$8.29 /

+0.105 (+1.28%)

Reports Q2 revenue $83M,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
SABR Sabre
$8.29 /

+0.105 (+1.28%)

SABR Sabre
$8.29 /

+0.105 (+1.28%)

05/11/20 Bernstein
Bernstein upgrades Sabre to Outperform ahead of air travel returning
05/11/20
Sabre upgraded to Outperform from Market Perform at Bernstein
04/13/20 Mizuho
Sabre price target raised to $5 from $3 at Mizuho
03/23/20 Mizuho
Sabre downgraded to Underperform from Buy at Mizuho
SABR Sabre
$8.29 /

+0.105 (+1.28%)

SABR Sabre
$8.29 /

+0.105 (+1.28%)

SABR Sabre
$8.29 /

+0.105 (+1.28%)

Upgrade
First Solar upgraded to Buy from Neutral at BofA » 07:42
08/07/20
08/07
07:42
08/07/20
07:42
FSLR

First Solar

$64.42 /

-1.315 (-2.00%)

BofA analyst Julien…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
FSLR First Solar
$64.42 /

-1.315 (-2.00%)

FSLR First Solar
$64.42 /

-1.315 (-2.00%)

07:00 Today UBS
First Solar price target raised to $75 from $63 at UBS
06:34 Today Roth Capital
First Solar price target raised to $65 from $56 at Roth Capital
06:27 Today Barclays
First Solar price target lowered to $45 from $51 at Barclays
07/27/20
Fly Intel: Top five analyst downgrades
FSLR First Solar
$64.42 /

-1.315 (-2.00%)

FSLR First Solar
$64.42 /

-1.315 (-2.00%)

FSLR First Solar
$64.42 /

-1.315 (-2.00%)

Hot Stocks
Arbutus Biopharma expects cash to fund operations into mid-2022 » 07:41
08/07/20
08/07
07:41
08/07/20
07:41
ABUS

Arbutus Biopharma

$4.39 /

+0.215 (+5.16%)

Arbutus had cash, cash…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ABUS Arbutus Biopharma
$4.39 /

+0.215 (+5.16%)

ABUS Arbutus Biopharma
$4.39 /

+0.215 (+5.16%)

07/27/20 B. Riley FBR
Arbutus Biopharma price target raised to $8 from $6 at B. Riley FBR
07/24/20 Baird
Arbutus Biopharma upside priced in, Baird downgrades to Neutral
07/24/20 Baird
Arbutus Biopharma downgraded to Neutral from Outperform at Baird
05/19/20 Wedbush
Arbutus Biopharma upgraded to Outperform at Wedbush following AB-729 data
ABUS Arbutus Biopharma
$4.39 /

+0.215 (+5.16%)

ABUS Arbutus Biopharma
$4.39 /

+0.215 (+5.16%)

Recommendations
PowerFleet price target raised to $8 from $6 at Ladenburg » 07:41
08/07/20
08/07
07:41
08/07/20
07:41
PWFL

PowerFleet

$5.95 /

-0.02 (-0.34%)

Ladenburg Thalmann…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
PWFL PowerFleet
$5.95 /

-0.02 (-0.34%)

PWFL PowerFleet
$5.95 /

-0.02 (-0.34%)

05/04/20 B. Riley FBR
PowerFleet downgraded to Neutral, target cut to $4.75 at B. Riley FBR
05/04/20 B. Riley FBR
PowerFleet downgraded to Neutral from Buy at B. Riley FBR
03/30/20 Roth Capital
PowerFleet resumed with a Buy at Roth Capital
10/04/19 Canaccord
PowerFleet contends in fleet management, initiated with a Buy at Canaccord
PWFL PowerFleet
$5.95 /

-0.02 (-0.34%)

Recommendations
Yeti price target raised to $65 from $55 at BTIG » 07:41
08/07/20
08/07
07:41
08/07/20
07:41
YETI

Yeti

$50.81 /

-0.86 (-1.66%)

BTIG analyst Camilo Lyon…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
YETI Yeti
$50.81 /

-0.86 (-1.66%)

YETI Yeti
$50.81 /

-0.86 (-1.66%)

06:29 Today KeyBanc
Yeti price target raised to $56 from $38 at KeyBanc
08/04/20 Baird
Baird remains bullish on Yeti Holdings' long-term growth story
07/30/20 BTIG
Yeti price target raised to $55 from $44 at BTIG
07/24/20 Stifel
Yeti price target raised to $45 from $33 at Stifel
YETI Yeti
$50.81 /

-0.86 (-1.66%)

  • 28
    May
  • 11
    May
  • 17
    Feb
  • 07
    Nov
YETI Yeti
$50.81 /

-0.86 (-1.66%)

YETI Yeti
$50.81 /

-0.86 (-1.66%)

Earnings
Arbutus Biopharma reports Q2 EPS (25c), consensus (24c) » 07:41
08/07/20
08/07
07:41
08/07/20
07:41
ABUS

Arbutus Biopharma

$4.39 /

+0.215 (+5.16%)

Reports Q2 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ABUS Arbutus Biopharma
$4.39 /

+0.215 (+5.16%)

ABUS Arbutus Biopharma
$4.39 /

+0.215 (+5.16%)

07/27/20 B. Riley FBR
Arbutus Biopharma price target raised to $8 from $6 at B. Riley FBR
07/24/20 Baird
Arbutus Biopharma upside priced in, Baird downgrades to Neutral
07/24/20 Baird
Arbutus Biopharma downgraded to Neutral from Outperform at Baird
05/19/20 Wedbush
Arbutus Biopharma upgraded to Outperform at Wedbush following AB-729 data
ABUS Arbutus Biopharma
$4.39 /

+0.215 (+5.16%)

ABUS Arbutus Biopharma
$4.39 /

+0.215 (+5.16%)

Recommendations
ViacomCBS price target raised to $35 from $24 at Benchmark » 07:41
08/07/20
08/07
07:41
08/07/20
07:41
VIAC

ViacomCBS

$26.88 /

+0.88 (+3.38%)

Benchmark analyst Daniel…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
VIAC ViacomCBS
$26.88 /

+0.88 (+3.38%)

VIAC ViacomCBS
$26.88 /

+0.88 (+3.38%)

07/13/20
Fly Intel: Top five analyst initiations
07/13/20
Fly Intel: Top five analyst downgrades
07/13/20 Wells Fargo
ViacomCBS price target raised to $19 from $13 at Wells Fargo
07/13/20 BofA
ViacomCBS downgraded to Neutral from Buy at BofA
VIAC ViacomCBS
$26.88 /

+0.88 (+3.38%)

VIAC ViacomCBS
$26.88 /

+0.88 (+3.38%)

VIAC ViacomCBS
$26.88 /

+0.88 (+3.38%)

VIAC ViacomCBS
$26.88 /

+0.88 (+3.38%)

Recommendations
Celsius Holdings price target raised to $23.50 from $11.75 at Ladenburg » 07:39
08/07/20
08/07
07:39
08/07/20
07:39
CELH

Celsius Holdings

$20.86 /

+5.25 (+33.63%)

Ladenburg analyst Jeffrey…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CELH Celsius Holdings
$20.86 /

+5.25 (+33.63%)

CELH Celsius Holdings
$20.86 /

+5.25 (+33.63%)

08/06/20 Roth Capital
Celsius Holdings price target raised to $25 from $14.50 at Roth Capital
07/28/20 B. Riley FBR
Celsius Holdings price target raised to $17 from $11.50 at B. Riley FBR
06/24/20 Maxim
Celsius Holdings price target raised to $15 from $12 at Maxim
04/30/20 Roth Capital
Celsius Holdings initiated with a Buy at Roth Capital
CELH Celsius Holdings
$20.86 /

+5.25 (+33.63%)

  • 12
    Sep
Earnings
PFSweb sees 2020 consolidated SFE revenue growth 9%-12% » 07:39
08/07/20
08/07
07:39
08/07/20
07:39
PFSW

PFSweb

$9.58 /

-0.065 (-0.67%)

Revenue consensus…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
PFSW PFSweb
$9.58 /

-0.065 (-0.67%)

PFSW PFSweb
$9.58 /

-0.065 (-0.67%)

08/03/20 B. Riley FBR
PFSweb price target raised to $9.50 from $7.50 at B. Riley FBR
05/08/20 Lake Street
PFSweb set to benefit from more direct to consumer sales, says Lake Street
01/06/20 Craig-Hallum
PFSweb upgraded to Buy from Hold at Craig-Hallum
11/12/19 Lake Street
Lake Street upgrades PFSweb to Buy, ups target to $5 from $4
PFSW PFSweb
$9.58 /

-0.065 (-0.67%)

Recommendations
Papa John's price target raised to $115 from $95 at BTIG » 07:38
08/07/20
08/07
07:38
08/07/20
07:38
PZZA

Papa John's

$97.38 /

-1.945 (-1.96%)

BTIG analyst Peter Saleh…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
PZZA Papa John's
$97.38 /

-1.945 (-1.96%)

PZZA Papa John's
$97.38 /

-1.945 (-1.96%)

06:45 Today Credit Suisse
Papa John's price target raised to $110 from $90 at Credit Suisse
07/27/20 Stephens
McDonald's, Domino's among restaurant stocks to own now, says Stephens
07/27/20 Longbow
Papa John's U.S. comps up high-teens percentage in recent weeks, says Longbow
07/01/20
Fly Intel: Top five analyst initiations
PZZA Papa John's
$97.38 /

-1.945 (-1.96%)

PZZA Papa John's
$97.38 /

-1.945 (-1.96%)

PZZA Papa John's
$97.38 /

-1.945 (-1.96%)

Recommendations
BeiGene price target raised to $268 from $232 at Ladenburg » 07:38
08/07/20
08/07
07:38
08/07/20
07:38
BGNE

BeiGene

$224.41 /

-1.59 (-0.70%)

Ladenburg analyst Wangzhi…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
BGNE BeiGene
$224.41 /

-1.59 (-0.70%)

BGNE BeiGene
$224.41 /

-1.59 (-0.70%)

08/06/20 Piper Sandler
BeiGene price target raised to $175 from $165 at Piper Sandler
07/21/20 Baird
Assembly Biosciences HBV deal a positive, says Baird
07/20/20 Piper Sandler
BeiGene inked smart deal with Assembly, says Piper Sandler
07/13/20 Maxim
BeiGene price target raised to $250 from $190 at Maxim
BGNE BeiGene
$224.41 /

-1.59 (-0.70%)

BGNE BeiGene
$224.41 /

-1.59 (-0.70%)

Earnings
PFSweb reports Q2 EPS (5c), consensus 0c » 07:38
08/07/20
08/07
07:38
08/07/20
07:38
PFSW

PFSweb

$9.58 /

-0.065 (-0.67%)

Reports Q2 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
PFSW PFSweb
$9.58 /

-0.065 (-0.67%)

PFSW PFSweb
$9.58 /

-0.065 (-0.67%)

08/03/20 B. Riley FBR
PFSweb price target raised to $9.50 from $7.50 at B. Riley FBR
05/08/20 Lake Street
PFSweb set to benefit from more direct to consumer sales, says Lake Street
01/06/20 Craig-Hallum
PFSweb upgraded to Buy from Hold at Craig-Hallum
11/12/19 Lake Street
Lake Street upgrades PFSweb to Buy, ups target to $5 from $4
PFSW PFSweb
$9.58 /

-0.065 (-0.67%)

Periodicals
TikTok in talks with at least 3 American companies over acquisition, NYT says » 07:37
08/07/20
08/07
07:37
08/07/20
07:37
MSFT

Microsoft

$216.32 /

+3.37 (+1.58%)

, TCEHY

Tencent

$0.00 /

+ (+0.00%)

TikTok is in talks with…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
MSFT Microsoft
$216.32 /

+3.37 (+1.58%)

TCEHY Tencent
$0.00 /

+ (+0.00%)

MSFT Microsoft
$216.32 /

+3.37 (+1.58%)

08/05/20 Morgan Stanley
Morgan Stanley says TikTok US operations could be 'compelling' fit for Microsoft
08/04/20 Wedbush
Wedbush sees 75%-80% chance of Microsoft buying TikTok's U.S. operations
08/04/20 Oppenheimer
TikTok presents 'unique opportunity' for Microsoft, says Oppenheimer
08/03/20 Wedbush
Wedbush sees a TikTok deal as big bet from Microsoft on social media space
TCEHY Tencent
$0.00 /

+ (+0.00%)

08/03/20 Morgan Stanley
Sohu.com named a Research Tactical Idea at Morgan Stanley
07/27/20 Barclays
Tencent price target raised to $75 from $63 at Barclays
07/14/20 Citi
Tencent price target raised to HK$649 from HK$541 at Citi
07/08/20 Mizuho
Tencent price target raised to HK$475 from HK$410 at Mizuho
MSFT Microsoft
$216.32 /

+3.37 (+1.58%)

TCEHY Tencent
$0.00 /

+ (+0.00%)

MSFT Microsoft
$216.32 /

+3.37 (+1.58%)

TCEHY Tencent
$0.00 /

+ (+0.00%)

MSFT Microsoft
$216.32 /

+3.37 (+1.58%)

TCEHY Tencent
$0.00 /

+ (+0.00%)

MSFT Microsoft
$216.32 /

+3.37 (+1.58%)

MSFT Microsoft
$216.32 /

+3.37 (+1.58%)

Hot Stocks
FDA accepts Biogen's aducanumab BLA for Alzheimer's with priority review » 07:37
08/07/20
08/07
07:37
08/07/20
07:37
BIIB

Biogen

$277.44 /

+1.3 (+0.47%)

, ESALY

Eisai

$0.00 /

+ (+0.00%)

Biogen (Nasdaq: BIIB) and…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
BIIB Biogen
$277.44 /

+1.3 (+0.47%)

ESALY Eisai
$0.00 /

+ (+0.00%)

BIIB Biogen
$277.44 /

+1.3 (+0.47%)

08/06/20 Goldman Sachs
Denali's LRRK2 program complementary to Biogen's PD pipeline, says Goldman Sachs
08/06/20 Wells Fargo
Biogen 'doubling down on LRRK2' via deal with Denali, says Wells Fargo
07/27/20
Fly Intel: Top five analyst upgrades
07/27/20 Morgan Stanley
Biogen double upgraded to Overweight from Underweight at Morgan Stanley
ESALY Eisai
$0.00 /

+ (+0.00%)

10/24/19 Nomura Instinet
Eisai upgraded to Buy from Neutral at Nomura Instinet
09/24/19 Jefferies
Eisai initiated with a Buy at Jefferies
09/17/19 Daiwa
Eisai downgraded to Sell from Neutral at Daiwa
BIIB Biogen
$277.44 /

+1.3 (+0.47%)

BIIB Biogen
$277.44 /

+1.3 (+0.47%)

BIIB Biogen
$277.44 /

+1.3 (+0.47%)

BIIB Biogen
$277.44 /

+1.3 (+0.47%)

Upgrade
Solar Senior Capital upgraded to Buy from Neutral at Ladenburg » 07:37
08/07/20
08/07
07:37
08/07/20
07:37
SUNS

Solar Senior Capital

$13.05 /

-0.24 (-1.81%)

Ladenburg analyst Mickey…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
SUNS Solar Senior Capital
$13.05 /

-0.24 (-1.81%)

SUNS Solar Senior Capital
$13.05 /

-0.24 (-1.81%)

Hot Stocks
Biogen jumps 10% to $305 after FDA accepts aducanumab with priority review  07:36
08/07/20
08/07
07:36
08/07/20
07:36
BIIB

Biogen

$277.44 /

+1.3 (+0.47%)

 
ShowHide Related Items >><<
BIIB Biogen
$277.44 /

+1.3 (+0.47%)

BIIB Biogen
$277.44 /

+1.3 (+0.47%)

08/06/20 Goldman Sachs
Denali's LRRK2 program complementary to Biogen's PD pipeline, says Goldman Sachs
08/06/20 Wells Fargo
Biogen 'doubling down on LRRK2' via deal with Denali, says Wells Fargo
07/27/20
Fly Intel: Top five analyst upgrades
07/27/20 Morgan Stanley
Biogen double upgraded to Overweight from Underweight at Morgan Stanley
BIIB Biogen
$277.44 /

+1.3 (+0.47%)

BIIB Biogen
$277.44 /

+1.3 (+0.47%)

BIIB Biogen
$277.44 /

+1.3 (+0.47%)

BIIB Biogen
$277.44 /

+1.3 (+0.47%)

Hot Stocks
Crinetics sees topline data from Edge, Evolve trials in Q4 » 07:36
08/07/20
08/07
07:36
08/07/20
07:36
CRNX

Crinetics

$14.83 /

+0.17 (+1.16%)

Confirmed completion for…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
CRNX Crinetics
$14.83 /

+0.17 (+1.16%)

CRNX Crinetics
$14.83 /

+0.17 (+1.16%)

05/11/20 Cantor Fitzgerald
Crinetics price target raised to $38 from $28 at Cantor Fitzgerald
05/08/20 Piper Sandler
Piper Sandler continues to recommend Crinetics after paltusotine data
04/07/20 Piper Sandler
Crinetics shares 'should be up meaningfully,' says Piper Sandler
12/23/19 Roth Capital
Crinetics initiated with a Buy at Roth Capital
CRNX Crinetics
$14.83 /

+0.17 (+1.16%)

  • 15
    Apr
CRNX Crinetics
$14.83 /

+0.17 (+1.16%)

Upgrade
Solar Capital upgraded to Buy from Neutral at Ladenburg » 07:36
08/07/20
08/07
07:36
08/07/20
07:36
SLRC

Solar Capital

$16.68 /

-0.07 (-0.42%)

Ladenburg Thalmann…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SLRC Solar Capital
$16.68 /

-0.07 (-0.42%)

SLRC Solar Capital
$16.68 /

-0.07 (-0.42%)

05/11/20 Deutsche Bank
Solar Capital price target lowered to $18.50 from $23.50 at Deutsche Bank
04/02/20 Compass Point
Solar Capital upgraded to Buy from Neutral at Compass Point
03/25/20 Wells Fargo
Solar Capital upgraded to Overweight from Equal Weight at Wells Fargo
02/24/20 Ladenburg
Solar Capital downgraded to Neutral from Buy at Ladenburg
SLRC Solar Capital
$16.68 /

-0.07 (-0.42%)

Earnings
Crinetics reports Q2 EPS (53c), consensus (57c) » 07:35
08/07/20
08/07
07:35
08/07/20
07:35
CRNX

Crinetics

$14.83 /

+0.17 (+1.16%)

"Crinetics has made…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
CRNX Crinetics
$14.83 /

+0.17 (+1.16%)

CRNX Crinetics
$14.83 /

+0.17 (+1.16%)

05/11/20 Cantor Fitzgerald
Crinetics price target raised to $38 from $28 at Cantor Fitzgerald
05/08/20 Piper Sandler
Piper Sandler continues to recommend Crinetics after paltusotine data
04/07/20 Piper Sandler
Crinetics shares 'should be up meaningfully,' says Piper Sandler
12/23/19 Roth Capital
Crinetics initiated with a Buy at Roth Capital
CRNX Crinetics
$14.83 /

+0.17 (+1.16%)

  • 15
    Apr
CRNX Crinetics
$14.83 /

+0.17 (+1.16%)

Earnings
Meridian Bioscience sees 2020 adj. EPS $1.01-$1.05, consensus 75c » 07:34
08/07/20
08/07
07:34
08/07/20
07:34
VIVO

Meridian Bioscience

$24.30 /

-2.09 (-7.92%)

Sees revenue $245M-$250M,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
VIVO Meridian Bioscience
$24.30 /

-2.09 (-7.92%)

VIVO Meridian Bioscience
$24.30 /

-2.09 (-7.92%)

07/27/20 H.C. Wainwright
Meridian Bioscience initiated with a Buy at H.C. Wainwright
05/11/20
Fly Intel: Top five analyst upgrades
05/11/20 William Blair
COVID testing drives Blair to upgrade Meridian for first time in 10 years
05/11/20 William Blair
Meridian Bioscience upgraded to Outperform from Market Perform at William Blair
VIVO Meridian Bioscience
$24.30 /

-2.09 (-7.92%)

VIVO Meridian Bioscience
$24.30 /

-2.09 (-7.92%)

Hot Stocks
Biogen's aducanumab assigned PDUFA target action date of March 7, 2021  07:33
08/07/20
08/07
07:33
08/07/20
07:33
BIIB

Biogen

$277.44 /

+1.3 (+0.47%)

, ESALY

Eisai

$0.00 /

+ (+0.00%)

 
ShowHide Related Items >><<
BIIB Biogen
$277.44 /

+1.3 (+0.47%)

ESALY Eisai
$0.00 /

+ (+0.00%)

BIIB Biogen
$277.44 /

+1.3 (+0.47%)

08/06/20 Goldman Sachs
Denali's LRRK2 program complementary to Biogen's PD pipeline, says Goldman Sachs
08/06/20 Wells Fargo
Biogen 'doubling down on LRRK2' via deal with Denali, says Wells Fargo
07/27/20
Fly Intel: Top five analyst upgrades
07/27/20 Morgan Stanley
Biogen double upgraded to Overweight from Underweight at Morgan Stanley
ESALY Eisai
$0.00 /

+ (+0.00%)

10/24/19 Nomura Instinet
Eisai upgraded to Buy from Neutral at Nomura Instinet
09/24/19 Jefferies
Eisai initiated with a Buy at Jefferies
09/17/19 Daiwa
Eisai downgraded to Sell from Neutral at Daiwa
BIIB Biogen
$277.44 /

+1.3 (+0.47%)

BIIB Biogen
$277.44 /

+1.3 (+0.47%)

BIIB Biogen
$277.44 /

+1.3 (+0.47%)

BIIB Biogen
$277.44 /

+1.3 (+0.47%)

Hot Stocks
Biogen reports FDA accepts aducanumab BLA for Alzheimer's with priority review  07:32
08/07/20
08/07
07:32
08/07/20
07:32
BIIB

Biogen

$277.44 /

+1.3 (+0.47%)

, ESALY

Eisai

$0.00 /

+ (+0.00%)

 
ShowHide Related Items >><<
BIIB Biogen
$277.44 /

+1.3 (+0.47%)

ESALY Eisai
$0.00 /

+ (+0.00%)

BIIB Biogen
$277.44 /

+1.3 (+0.47%)

08/06/20 Goldman Sachs
Denali's LRRK2 program complementary to Biogen's PD pipeline, says Goldman Sachs
08/06/20 Wells Fargo
Biogen 'doubling down on LRRK2' via deal with Denali, says Wells Fargo
07/27/20
Fly Intel: Top five analyst upgrades
07/27/20 Morgan Stanley
Biogen double upgraded to Overweight from Underweight at Morgan Stanley
ESALY Eisai
$0.00 /

+ (+0.00%)

10/24/19 Nomura Instinet
Eisai upgraded to Buy from Neutral at Nomura Instinet
09/24/19 Jefferies
Eisai initiated with a Buy at Jefferies
09/17/19 Daiwa
Eisai downgraded to Sell from Neutral at Daiwa
BIIB Biogen
$277.44 /

+1.3 (+0.47%)

BIIB Biogen
$277.44 /

+1.3 (+0.47%)

BIIB Biogen
$277.44 /

+1.3 (+0.47%)

BIIB Biogen
$277.44 /

+1.3 (+0.47%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.